Cargando…

Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells

Fibrosis is a severe complication of chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Current strategies are not fully effective in treating fibrosis; therefore, innovative anti-fibrotic approaches are urgently needed. TGF-β1 plays a central role in the fibrotic process by i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Francesca, Augello, Francesca Rosaria, Palumbo, Paola, Mollsi, Elona, Giuliani, Maurizio, Cimini, Anna Maria, Cifone, Maria Grazia, Cinque, Benedetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998462/
https://www.ncbi.nlm.nih.gov/pubmed/33803197
http://dx.doi.org/10.3390/nu13030882
_version_ 1783670557803282432
author Lombardi, Francesca
Augello, Francesca Rosaria
Palumbo, Paola
Mollsi, Elona
Giuliani, Maurizio
Cimini, Anna Maria
Cifone, Maria Grazia
Cinque, Benedetta
author_facet Lombardi, Francesca
Augello, Francesca Rosaria
Palumbo, Paola
Mollsi, Elona
Giuliani, Maurizio
Cimini, Anna Maria
Cifone, Maria Grazia
Cinque, Benedetta
author_sort Lombardi, Francesca
collection PubMed
description Fibrosis is a severe complication of chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Current strategies are not fully effective in treating fibrosis; therefore, innovative anti-fibrotic approaches are urgently needed. TGF-β1 plays a central role in the fibrotic process by inducing myofibroblast differentiation and excessive extracellular matrix (ECM) protein deposition. Here, we explored the potential anti-fibrotic impact of two high concentration multi-strain probiotic formulations on TGF-β1-activated human intestinal colonic myofibroblast CCD-18Co. Human colonic fibroblast CCD-18Co cells were cultured in the presence of TGF-β1 to develop a fibrotic phenotype. Cell viability and growth were measured using the Trypan Blue dye exclusion test. The collagen-I, α-SMA, and pSmad2/3 expression levels were evaluated by Western blot analysis. Fibrosis markers were also analyzed by immunofluorescence and microscopy. The levels of TGF-β1 in the culture medium were assessed by ELISA. The effects of commercially available probiotic products VSL#3(®) and Vivomixx(®) were evaluated as the soluble fraction of bacterial lysates. The results suggested that the soluble fraction of Vivomixx(®) formulation, but not VSL#3(®), was able to antagonize the pro-fibrotic effects of TGF-β1 on CCD-18Co cells, being able to prevent all of the cellular and molecular parameters that are related to the fibrotic phenotype. The mechanism underlying the observed effect appeared to be associated with inhibition of the TGF-β1/Smad signaling pathway. To our knowledge, this study provides the first experimental evidence that Vivomixx(®) could be considered to be a promising candidate against intestinal fibrosis, being able to antagonize TGF-β1 pro-fibrotic effects. The differences that were observed in our fibrosis model between the two probiotics used could be attributable to the different number of strains in different proportions.
format Online
Article
Text
id pubmed-7998462
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79984622021-03-28 Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells Lombardi, Francesca Augello, Francesca Rosaria Palumbo, Paola Mollsi, Elona Giuliani, Maurizio Cimini, Anna Maria Cifone, Maria Grazia Cinque, Benedetta Nutrients Article Fibrosis is a severe complication of chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Current strategies are not fully effective in treating fibrosis; therefore, innovative anti-fibrotic approaches are urgently needed. TGF-β1 plays a central role in the fibrotic process by inducing myofibroblast differentiation and excessive extracellular matrix (ECM) protein deposition. Here, we explored the potential anti-fibrotic impact of two high concentration multi-strain probiotic formulations on TGF-β1-activated human intestinal colonic myofibroblast CCD-18Co. Human colonic fibroblast CCD-18Co cells were cultured in the presence of TGF-β1 to develop a fibrotic phenotype. Cell viability and growth were measured using the Trypan Blue dye exclusion test. The collagen-I, α-SMA, and pSmad2/3 expression levels were evaluated by Western blot analysis. Fibrosis markers were also analyzed by immunofluorescence and microscopy. The levels of TGF-β1 in the culture medium were assessed by ELISA. The effects of commercially available probiotic products VSL#3(®) and Vivomixx(®) were evaluated as the soluble fraction of bacterial lysates. The results suggested that the soluble fraction of Vivomixx(®) formulation, but not VSL#3(®), was able to antagonize the pro-fibrotic effects of TGF-β1 on CCD-18Co cells, being able to prevent all of the cellular and molecular parameters that are related to the fibrotic phenotype. The mechanism underlying the observed effect appeared to be associated with inhibition of the TGF-β1/Smad signaling pathway. To our knowledge, this study provides the first experimental evidence that Vivomixx(®) could be considered to be a promising candidate against intestinal fibrosis, being able to antagonize TGF-β1 pro-fibrotic effects. The differences that were observed in our fibrosis model between the two probiotics used could be attributable to the different number of strains in different proportions. MDPI 2021-03-09 /pmc/articles/PMC7998462/ /pubmed/33803197 http://dx.doi.org/10.3390/nu13030882 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Lombardi, Francesca
Augello, Francesca Rosaria
Palumbo, Paola
Mollsi, Elona
Giuliani, Maurizio
Cimini, Anna Maria
Cifone, Maria Grazia
Cinque, Benedetta
Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title_full Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title_fullStr Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title_full_unstemmed Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title_short Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells
title_sort soluble fraction from lysate of a high concentration multi-strain probiotic formulation inhibits tgf-β1-induced intestinal fibrosis on ccd-18co cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998462/
https://www.ncbi.nlm.nih.gov/pubmed/33803197
http://dx.doi.org/10.3390/nu13030882
work_keys_str_mv AT lombardifrancesca solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT augellofrancescarosaria solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT palumbopaola solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT mollsielona solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT giulianimaurizio solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT ciminiannamaria solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT cifonemariagrazia solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells
AT cinquebenedetta solublefractionfromlysateofahighconcentrationmultistrainprobioticformulationinhibitstgfb1inducedintestinalfibrosisonccd18cocells